26.10 USD
▲-1.36+1.40%
盘后 25.74 0.00%
2026-08-03
市值
$1.71B
市盈率
—
EPS
-2.80
股息率
—
52 周区间
9.57 – 30.99
成交量
815.07K
Beta
—
目标价
31.46
52W 低 9.5752W 高 30.99
价格走势
公司简介
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.